Navigation Links
Interview: Dr. William Yasnoff on health records, part 2

For this special issue of Wisconsin Technology Network, we asked William Yasnoff, founder of the eHealthTrust initiative, why his system can foster the adoption of electronic health records that today are fractured and limited.

Read part 1 of this interview.

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Interview William Yasnoff health records part

(Date:3/30/2015)... 30, 2015    Intrexon Corporation (NYSE: ... and Merck Serono, the biopharmaceutical business of Merck ... announced an exclusive strategic collaboration and license agreement ... (CAR-T) cancer therapies. This collaboration advances Merck Serono,s ... modulate the immune system,s natural ability to fight ...
(Date:3/30/2015)... FLORHAM PARK, N.J. , March 30, 2015 ... antagonist (PAMORA) under development by Shionogi & Co., ... a phase III study (COMPOSE I) for the ... with chronic non-cancer pain receiving opioid therapy. Study ... once daily) statistically significantly improved the frequency of ...
(Date:3/29/2015)... 29, 2015  Caris Life Sciences® today ... small cell cervical cancer (SCCC) that shows ... the company,s panomic, comprehensive tumor profiling service, identified ... may explain sensitivities and resistance to common ... certain biomarkers may guide treatment strategies in ...
(Date:3/27/2015)... The consumption of compound fertilizers (NPK) ... and high prices in 2008. However, the situation has ... on gaining momentum now. , To date, the world ... 100,000 thousand tonnes. No considerable growth was registered in ... rocketed during 2012-2013, registering 11% growth as against the ...
Breaking Biology Technology:Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 2Study Using Caris Molecular Intelligence Multiplatform Tumor Profiling Identifies Potential Treatment Strategies for Small Cell Cervical Cancer 3World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 2World NPK Fertilizers Market Keeps On Gaining Momentum, According to BAC Reports Study Available at MarketPublishers.com 3
... April 14 ,Monogram Biosciences, Inc. (Nasdaq: MGRM ) ... scheduled to present a corporate overview at,the Seventh Annual ... 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) at ... the live audio broadcast or the subsequent archived,recording, log ...
... ... product immediately, NATICK, Mass., April 14 Boston Scientific,Corporation ... Labor,and Welfare (MHLW) approval of its ACUITY(R) Steerable left ventricular,lead ... failure. The Company also received reimbursement approval for,the lead from ...
... SGP ) is scheduled to announce its sales and ... 23, 2008., At 8 a.m. (EDT) on that ... for the 2008 first quarter and provide an update ... Fred Hassan,Schering-Plough,s chairman and CEO, and other members of ...
Cached Biology Technology:Monogram Biosciences to Present at the JMP Securities Seventh Annual Research Conference 2Boston Scientific Announces Japanese Approval of Heart Failure Lead 2Boston Scientific Announces Japanese Approval of Heart Failure Lead 3Schering-Plough Schedules Conference Call and Webcast for 2008 First Quarter Earnings 2
(Date:3/10/2015)... , March 10, 2015 ... "Personalized Medicine in Human Space Flight" ... Thomas J. Goodwin , Ph.D. was recently featured ... the past two years. Specifically, "Personalized Medicine ... downloaded scientific papers published in 2013 and 2014 from ...
(Date:3/4/2015)... 2015 Research and Markets ( ... "Global Biometrics Market Forecast and Opportunities, 2020" ... market for biometric authentication systems is projected to ... 2020 The driving forces for this ... government projects and constant development in technology. In ...
(Date:3/2/2015)... , March 2, 2015   Neurotechnology , ... today introduced the SentiGaze Software Development Kit ... create applications that use off-the-shelf webcams to track eye ... gazes at a monitor. Heatmaps can be used for ... effectiveness of online advertising. The SDK can also be ...
Breaking Biology News(10 mins):"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 2Neurotechnology Releases SentiGaze SDK for Eye Movement Tracking Using Ordinary Webcams 3
... A team of bioengineers from the University of Pennsylvania ... neural network model to accurately predict how blood platelets ... attack or stroke. Using an automated, robotic system, ... combinations of biological stimuli like those experienced during a ...
... the U.S. Department of Energy,s (DOE) Argonne National Laboratory, ... a mind-boggling speed of over 557 trillion calculations a ... cutting-edge research in just weeks or months rather than ... science science that will change our world," said ...
... 18, 2010) In the year since their 2008 preliminary ranking, ... Host and Microbe saw their Impact Factors surge, according to ... ThomsonReuters. In the report released June 17, Cell Stem ... from the journal,s previous score. Cell Host and Microbe ...
Cached Biology News:Penn bioengineers create simulator to test blood platelets in virtual heart attacks 2Penn bioengineers create simulator to test blood platelets in virtual heart attacks 3Over two billion hours served 2New 2009 Impact Factors soar for newest Cell Press journals 2
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
Anti-Potassium Channel Kv2.2 Immunogen: Synthetic peptide from rat Kv2.2. Available Date: 38376...
Antibeta-lactoglobulin monoclonal antibody(CD-2)...
... clone 8G8/5 GenBank Accession Number : ... AP-2alpha/gamma fusion protein corresponding to residues 166-223 ... human AP-2γ Formulation: 0.1M Tris-glycine, pH 7.4, ... addition of glycerol to 30% Quality Assurance: ...
Biology Products: